ZIM Laboratories has received approval for investment of upto Rs 2 crore in equity shares of ZIMTAS, subsidiary of the company. The Investment is with an objective of Business Development in Australian and New Zealand markets. With the proposed investment, the company’s shareholding in ZIMTAS will change from 99% to 99.97%. The Board of Directors of the company in their meeting held on May 13, 2024 has inter-alia considered and approved the same.
ZIM Laboratories manufactures, formulates, and distributes drug delivery systems to develops generic pharmaceutical products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: